ArticleThe Korean journal of parasitology2013
Efficacy of a DNA vaccine carrying Eimeria maxima Gam56 antigen gene against coccidiosis in chickens.
Article in The Korean journal of parasitology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 33 citations in OpenAlex.
- Insight into poultry coccidiosis: a dual focus on anticoccidial drugs and herbal plants for pharmacological and prevention strategies.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2025Review
- Cloning, expression and purification ofJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2023Article
- What Do We Know about Surface Proteins of Chicken ParasitesLife (Basel, Switzerland) · 2023Review
- Vaccines against chicken coccidiosis with particular reference to previous decade: progress, challenges, and opportunities.Parasitology research · 2022Review
- A multiepitope vaccine encoding four Eimeria epitopes with PLGA nanospheres: a novel vaccine candidate against coccidiosis in laying chickens.Veterinary research · 2022Article
- Coccidiosis: Recent Progress in Host Immunity and Alternatives to Antibiotic Strategies.Vaccines · 2022Review
- Recombinant GMA56 and ROP17 ofFrontiers in immunology · 2022Article
- Sexual Development in Non-Human Parasitic Apicomplexa: Just Biology or Targets for Control?Animals : an open access journal from MDPI · 2021Review
- Characterization of Cystoisospora suis sexual stages in vitro.Parasites & vectors · 2020Article
- Recent advances in delivery of veterinary DNA vaccines against avian pathogens.Veterinary research · 2019Review
- A review of Eimeria antigen identification for the development of novel anticoccidial vaccines.Parasitology research · 2019Review
- Immunoprophylactic evaluation of recombinant gametocyte 22 antigen of Eimeria tenella in broiler chickens.Parasitology research · 2019Article
- DNA vaccination of poultry: The current status in 2015.Vaccine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To control coccidiosis without using prophylactic medications, a DNA vaccine targeting the gametophyte antigen Gam56 from Eimeria maxima in chickens was constructed, and the immunogenicity and protective effects were evaluated. The ORF of Gam56 gene was cloned into an eukaryotic expression vector pcDNA3.1(zeo)+. Expression of Gam56 protein in COS-7 cells transfected with recombinant plasmid pcDNA-Gam56 was confirmed by indirect immunofluorescence assay. The DNA vaccine was injected intramuscularly to yellow feathered broilers of 1-week old at 3 dosages (25, 50, and 100 µg/chick). Injection was repeated once 1 week later. One week after the second injection, birds were challenged orally with 5×10(4) sporulated oocysts of E. maxima, then weighed and killed at day 8 post challenge. Blood samples were collected and examined for specific peripheral blood lymphocyte proliferation activity and serum antibody levels. Compared with control groups, the administration of pcDNA-Gam56 vaccine markedly increased the lymphocyte proliferation activity (P<0.05) at day 7 and 14 after the first immunization. The level of lymphocyte proliferation started to decrease on day 21 after the first immunization. A similar trend was seen in specific antibody levels. Among the 3 pcDNA-Gam56 immunized groups, the median dosage group displayed the highest lymphocyte proliferation and antibody levels (P<0.05). The median dosage group had the greatest relative body weight gain (89.7%), and the greatest oocyst shedding reduction (53.7%). These results indicate that median dosage of DNA vaccine had good immunogenicity and immune protection effects, and may be used in field applications for coccidiosis control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.